Literature DB >> 10837200

Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.

B P Mahon1, M T Brady, K H Mills.   

Abstract

Most vaccines used for humans work through humoral immunity, yet many appear to be protective even after specific circulating antibody levels have waned to undetectable levels. Furthermore, it has been difficult to define a serologic correlate of protection against a number of infectious diseases, including those caused by Bordetella pertussis. B. pertussis clearance in immunized mice has been shown to correlate with pertussis vaccine efficacy in children. This murine respiratory challenge model was used to demonstrate persistent vaccine-induced protection against B. pertussis in the absence of circulating antibody at the time of challenge. Whole-cell and acellular pertussis vaccines induced persistent memory T and B cells and anamnestic antibody responses after challenge. The findings suggest that immunologic memory is more significant in protection than is the induction of immediate antibody responses and imply that vaccinated children still may be protected against disease following the disappearance of specific serum IgG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837200     DOI: 10.1086/315527

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.

Authors:  E J Ryan; L Nilsson; N Kjellman; L Gothefors; K H Mills
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

5.  Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.

Authors:  Claudius U Meyer; Fred Zepp; Michael Decker; Martin Lee; Swei-Ju Chang; Joel Ward; Sandra Yoder; Hugues Bogaert; Kathryn M Edwards
Journal:  Clin Vaccine Immunol       Date:  2007-01-31

6.  Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.

Authors:  Maja Jahnmatz; Margaretha Ljungman; Eva Netterlid; Maria C Jenmalm; Lennart Nilsson; Rigmor Thorstensson
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

7.  A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.

Authors:  A Dunne; L A Mielke; A C Allen; C E Sutton; R Higgs; C C Cunningham; S C Higgins; K H G Mills
Journal:  Mucosal Immunol       Date:  2014-10-15       Impact factor: 7.313

8.  Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model.

Authors:  Darren P Ennis; Joseph P Cassidy; Bernard P Mahon
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

Authors:  Ciaran M Skerry; Joseph P Cassidy; Karen English; Pascal Feunou-Feunou; Camille Locht; Bernard P Mahon
Journal:  Clin Vaccine Immunol       Date:  2009-07-22

10.  Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Authors:  Jeroen Geurtsen; H Alexander Banus; Eric R Gremmer; Henke Ferguson; Liset J J de la Fonteyne-Blankestijn; Jolanda P Vermeulen; Jan A M A Dormans; Jan Tommassen; Peter van der Ley; Frits R Mooi; Rob J Vandebriel
Journal:  Clin Vaccine Immunol       Date:  2007-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.